HB Wealth Management LLC Boosts Holdings in Zoetis Inc. $ZTS

Key Points

• HB Wealth Management increased its Zoetis stake by 190% during the second quarter, ending with 38,820 shares valued at approximately $2.79 million. Institutional investors collectively own 92.8% of Zoetis.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $101.08 after several firms lowered their targets.
• Zoetis shares opened at $73.56, near their 52-week low of $71.00. The company slightly exceeded quarterly EPS estimates, reporting $1.87 per share, while revenue declined 0.2% year over year to $2.47 billion.

HB Wealth Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 190.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,820 shares of the company's stock after acquiring an additional 25,433 shares during the quarter. HB Wealth Management LLC's holdings in Zoetis were worth $2,790,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. RFG Advisory LLC boosted its position in shares of Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company's stock valued at $215,000 after purchasing an additional 80 shares during the period. Financial Engines Advisors L.L.C. increased its position in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company's stock worth $299,000 after buying an additional 87 shares during the period. Physician Wealth Advisors Inc. lifted its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company's stock valued at $73,000 after buying an additional 91 shares during the last quarter. Smithfield Trust Co lifted its stake in Zoetis by 4.2% in the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company's stock valued at $290,000 after buying an additional 92 shares during the last quarter. Finally, Howland Capital Management LLC boosted its holdings in shares of Zoetis by 4.5% in the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company's stock valued at $333,000 after acquiring an additional 92 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ZTS shares. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research report on Monday, August 10th. Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 1st. Citigroup decreased their price target on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. William Blair reissued a "market perform" rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, UBS Group dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $101.08.

Zoetis Stock Performance

Shares of ZTS opened at $73.56 on Wednesday. The stock has a market capitalization of $30.40 billion, a P/E ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $152.12. The company's fifty day moving average is $75.61 and its two-hundred day moving average is $92.87.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business's revenue was down .2% on a year-over-year basis. During the same quarter last year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.